ALTRUBIO RAISES $63 MILLION SERIES A ROUND TO CONTINUE ITS COMPANY TRANSFORMATION
AltruBio’s Neihulizumab Granted Fast Track Designation by the FDA for Steroid Refractory Acute Graft Versus Host Disease
AltruBio to present at Biotech Showcase Digital 2021.
AltruBio Presented its Novel PSGL-1 Agonist Antibody Program for Immunological Diseases at FOCIS and Presented its Phase 2a Psoriatic Arthritis study results for lead molecule, Neihulizumab (AbGn-168H), at ACR.
AltruBio Announces First Patient Dosed in Phase 1b Study of Neihulizumab in Patients with Steroid-Refractory Acute Graft-versus-Host Disease.
AltruBio Inc. moves forward with clinical development of Neihulizumab in Steroid-Refractory Acute Graft-versus-Host Disease after encouraging Phase 1a results